Arctic Bioscience – CFO change

Arctic Bioscience, a biotech company developing and commercializing pharmaceutical and nutraceutical products based on the unique properties of bioactive marine compounds, announces that CFO Danielle Glenn has terminated her consulting agreement and accepted a position with another company. Glenn has been with the company since September 2020. The search for a new permanent CFO has been initiated.

“Arctic Bioscience has taken major steps over the past years, with several initiatives in both pharma and nutraceuticals and the development of a new production facility at the North- West coast of Norway. In addition, the company has listed on the Euronext Growth platform, supporting the company’s growth strategy. I would like to thank Danielle for her contributions to this development”, says Harald Nordal, Chairman of the Board in Arctic Bioscience.

“Arctic Bioscience will continue to capture its commercial and strategic opportunities, develop new alliances and execute on the upcoming phase II study for our psoriasis drug candidate. Our incoming CEO Christer Valderhaug will align his management team, including the new CFO with this exciting growth strategy “, says Nordal

Danielle Glenn will continue as CFO through April 2022.